GLP-1 Receptor Agonist [EPC]

204698 reported adverse events

Drugs of this class: SEMAGLUTIDE LIRAGLUTIDE DULAGLUTIDE EXENATIDE (INSULIN DEGLUDEC AND LIRAGLUTIDE) INSULIN GLARGINE AND LIXISENATIDE LIXISENATIDE ORAL SEMAGLUTIDE

These side effects are most commonly reported by patients taking drugs of the GLP-1 Receptor Agonist [EPC] class:

#	Side effect	Count
0	NAUSEA	30877
1	BLOOD GLUCOSE INCREASED	30756
2	WEIGHT DECREASED	20085
3	INJECTION SITE PAIN	14373
4	VOMITING	13601
5	DIARRHOEA	12179
6	DECREASED APPETITE	11864
7	INJECTION SITE HAEMORRHAGE	9491
8	BLOOD GLUCOSE DECREASED	9131
9	HEADACHE	6665

See all common reactions for GLP-1 Receptor Agonist [EPC]

Drugs of the GLP-1 Receptor Agonist [EPC] class are most commonly taken among patients reporting these side effects:

#	Side effect	Count	Frequency
0	EARLY SATIETY	698	0.4647
1	MEDULLARY THYROID CANCER	82	0.3981
2	GLYCOSYLATED HAEMOGLOBIN ABNORMAL	214	0.3359
3	INJECTION SITE NODULE	3066	0.3350
4	DRUG DELIVERY SYSTEM ISSUE	317	0.3129
5	INTENTIONAL DEVICE MISUSE	1244	0.3101
6	ACCIDENTAL UNDERDOSE	1884	0.2947
7	INJECTION SITE EXTRAVASATION	3212	0.2757
8	GLYCOSYLATED HAEMOGLOBIN DECREASED	290	0.2656
9	PANCREATIC CARCINOMA METASTATIC	599	0.2472

See all enriched reactions for GLP-1 Receptor Agonist [EPC]